WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 564620
Description: OSU-T315 (1,5-regioisomer) is a potent and specific integrin-linked kinase (ILK) inhibitor which inhibits PDK2 function in the AKT pathway activation, showing a specific mechanism of abrogating the AKT pathway and inhibition of BCR activity in the leukemic cell. OSU-T315 also acts as a selective inhibitor of biofilm formation.
MedKoo Cat#: 564620
Name: OSU-T315 (1,5-regioisomer)
Chemical Formula: C30H30F3N5O
Exact Mass: 533.2402
Molecular Weight: 533.6
Elemental Analysis: C, 67.53; H, 5.67; F, 10.68; N, 13.13; O, 3.00
Synonym: ILK inhibitor 22(1,5); T315(1,5); OSU-T315 (1,5-regioisomer); OSUT315; OSU T315; OSU-T315; CPD 22; CPD22; CPD-22
IUPAC/Chemical Name: N-Methyl-3-[1-(4-piperazin-1-yl-phenyl)-5-(4'-trifluoromethyl-biphenyl-4-yl)-1H-pyrazol-3-yl]-propionamide
InChi Key: GHBUPSVATJKTRR-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H30F3N5O/c1-34-29(39)15-10-25-20-28(38(36-25)27-13-11-26(12-14-27)37-18-16-35-17-19-37)23-4-2-21(3-5-23)22-6-8-24(9-7-22)30(31,32)33/h2-9,11-14,20,35H,10,15-19H2,1H3,(H,34,39)
SMILES Code: O=C(NC)CCC1=NN(C2=CC=C(N3CCNCC3)C=C2)C(C4=CC=C(C5=CC=C(C(F)(F)F)C=C5)C=C4)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 533.6 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Van Belle K, Herman J, Waer M, Sprangers B, Louat T. OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics. J Immunol Res. 2018 Sep 12;2018:2505818. doi: 10.1155/2018/2505818. eCollection 2018. PubMed PMID: 30276218; PubMed Central PMCID: PMC6157143.
2: Mercado-Pimentel ME, Igarashi S, Dunn AM, Behbahani M, Miller C, Read CM, Jacob A. The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation. Austin J Med Oncol. 2016;3(1). pii: 1025. Epub 2016 Apr 21. PubMed PMID: 27642646; PubMed Central PMCID: PMC5024787.
3: Robak T, Smolewski P. Novel target to kill CLL. Blood. 2015 Jan 8;125(2):211-2. doi: 10.1182/blood-2014-10-606582. PubMed PMID: 25573966.
4: Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 2015 Jan 8;125(2):284-95. doi: 10.1182/blood-2014-06-583518. Epub 2014 Oct 7. PubMed PMID: 25293770; PubMed Central PMCID: PMC4287637.